Gene ESR1 como biomarcador preditivo e prognóstico em câncer de mama: uma revisão sistemática
Palavras-chave:
câncer de mama, ESR1, preditivo, prognósticoResumo
No cenário atual do câncer de mama novos biomarcadores genéticos com valores preditivo e prognóstico têm sido buscados, sendo o gene ESR1 extremamente relevante nesse contexto. Desse modo, o presente trabalho objetivou identificar e selecionar evidências acerca do gene ESR1 como biomarcador preditivo e prognóstico da doença, segundo a realização de uma revisão sistemática da literatura, por meio das bases de dados PubMed e Science Direct, segundo critérios de inclusão e exclusão estabelecidos. Foram encontrados 491 artigos correlatos, sendo 29 selecionadas para serem avaliadas para elegibilidade em texto completo, de modo que foram selecionados 10 artigos para a síntese qualitativa do presente trabalho. Os achados demonstram o papel do ESR1 como potencial biomarcador preditivo e prognóstico ao câncer de mama, sendo amplificações, ganhos e deleções relevantes, seja comparado à expressão do receptor de estrogênio (RE), seja quanto aos esquemas terapêuticos. Contudo, mais estudos clínicos são necessários, seja para elucidar efetivamente o mecanismo molecular do gene em questão, seja para que sua compreensão seja ainda mais específica, a fim de que a sua aplicação seja mais efetiva no contexto em questão.
Downloads
Referências
BAYLEY, R., WARD, C., GARCIA, P. (2020). MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188407.
BEIJE, N., ONSTENK, W., KRAAN, J. et al. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 2016 Nov;18(11):647-653.
BRAY, F., FERLAY, J., SOERJOMATARAM, I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world- wide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394–424.
BUDCZIES, J., BOCKMAYR, M. DENKERT, C. et al. (2015). Classical pathology and mutational load of breast cancer - integration of two worlds, J Pathol Clin Res 1 (2015) 225–238.
CALLARI, M., MUSELLA, V., DI BUDUO, E. et al. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. Mol Oncol. 2014 Oct;8(7):1278-89.
CHEN, Y., CHEN, C., YANG, B. et al. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 2011 Mar 1;302(1):63-8.
DOAN, T.B., ERIKSSON, N.A. et al. Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Mol Oncol. 2014 Jul;8(5):998-1013.
EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386:1341–52.
FRANKEN, A., HONISCH, E., REINHARDT, F. et al. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. J Mol Diagn. 2020 Jan;22(1):111-121.
LAENKHOLM, A.V., KNOOP, A., EJLERTSEN, B. et al. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Mol Oncol. 2012 Aug;6(4):428-36.
LAFOURCADE, A., HIS, M., BAGLIETTO, L. et al. Factors associated with breast cancer recurrences or mortality and dynamic pre- diction of death using history of cancer recurrences: the French E3N cohort, BMC Cancer 18 (2018) 171.
LAUSS, M., KRIEGNER, A., VIERLINGER, K. et al. (2008). Consensus genes of the literature to predict breast cancer recurrence, Breast Cancer Res. Treat. 110 (2008) 235–244.
LI, X., LU, J., ZHANG, L. et al. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study. Transl Oncol. 2020 Feb;13(2):321-328.
NATIONAL CANCER INSTITUTE SURVEILLANCE EPIDEMIOLOGY AND END RESULTS PROGRAM. Cancer stat facts: female breast cancer subtypes: NIH; 2017. https://seer.cancer.gov/statfacts/html/breastsubtypes.%20html#:~:text=The%20breast%cancer%subtype%HR,based%on%202013%E2%80%932017%20cases.
NCC Breast Cancer. Network. (Version 6.2020). 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. [Ref list]
ROSS, D.S., ZEHIR, A., BROGI, E. et al. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Mod Pathol. 2019 Jan;32(1):81-87.
SHI, H., BEVIER, M., JOHANSSON, R. et al. (2011b). Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):1039-47.
STATBITE, StatBite Breast Cancer: 5-Year Survival Rates in U.S. for Selected Histologic Types by Stage, JNCI: Journal of the National Cancer Institute 101 (2009) 1303.
TSEZOU, A., TZETIS, M., GENNATAS, C. et al. Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. Breast. 2008;17:159–166.
WILSON, F.R., COOMBES, M.E., BREZDEN-MASLEY, C. et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis, Syst Rev 7 (2018) 191.
WU, J.R., ZHAO, Y., ZHOU, X.P. et al. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Biomed Pharmacother. 2020 Jan; 121: 109647.
